Search

Your search keyword '"Antiviral agents -- Testing"' showing total 235 results
Start Over Descriptor "Antiviral agents -- Testing" Topic health care industry
235 results on '"Antiviral agents -- Testing"'

1. Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment

Author

Grudda, Tanner, Hwang, Hyon S., Taddese, Maraake, Quinn, Jeffrey, Sulkowski, Mark S., Sterling, Richard K., Balagopal, Ashwin, and Thio, Chloe L.

Subjects
DNA -- Health aspects, Antiviral agents -- Testing, Hepatitis B -- Drug therapy, Hepatitis associated antigen -- Genetic aspects, Host-virus relationships -- Genetic aspects, Health care industry
Abstract

The focus of hepatitis B functional cure, defined as sustained loss of hepatitis B virus (HBV) surface antigen (HBsAg) and HBV DNA from blood, is on eliminating or silencing the intranuclear template for HBV replication, covalently closed circular DNA (cccDNA). However, HBsAg also derives from HBV DNA integrated into the host genome (iDNA). Little is known about the contribution of iDNA to circulating HBsAg with current therapeutics. We applied a multiplex droplet digital PCR assay to demonstrate that iDNA is responsible for maintaining HBsAg quantities in some individuals. Using paired bulk liver tissue from 16 HIV/HBV-coinfected persons on nucleos(t)ide analog (NUC) therapy, we demonstrate that people with larger HBsAg declines between biopsies derive HBsAg from cccDNA, whereas people with stable HBsAg levels derive predominantly from iDNA. We applied our assay to individual hepatocytes in paired tissues from 3 people and demonstrated that the individual with significant HBsAg decline had a commensurate loss of infected cells with transcriptionally active cccDNA, while individuals without HBsAg decline had stable or increasing numbers of cells producing HBsAg from iDNA. We demonstrate that while NUC therapy may be effective at controlling cccDNA replication and transcription, innovative treatments are required to address iDNA transcription that sustains HBsAg production., Introduction For the nearly 300 million people chronically infected with hepatitis B virus (HBV), current treatments, which include pegylated interferon a (PEG-IFN-[alpha]) and nucleos(t)ide analogs (NUCs), uncommonly result in cure, [...]

Published
2022
Full Text
View/download PDF

2. Rapamycin limits [CD4.sup.+] T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy

Author

Varco-Merth, Benjamin D., Brantley, William, Marenco, Alejandra, Duell, Derick D., Fachko, Devin N., Richardson, Brian, Busman-Sahay, Kathleen, Shao, Danica, Flores, Walter, Engelman, Kathleen, Fukazawa, Yoshinori, Wong, Scott W., Skalsky, Rebecca L., Smedley, Jeremy, Axthelm, Michael K., Lifson, Jeffrey D., Estes, Jacob D., Edlefsen, Paul T., Picker, Louis J., Cameron, Cheryl M.A., Henrich, Timothy J., and Okoye, Afam A.

Subjects
Rhesus monkey -- Drug therapy, Antiviral agents -- Testing, T cell proliferation -- Research, Rapamycin -- Testing, HIV infection -- Drug therapy -- Models, Health care industry
Abstract

Proliferation of latently infected [CD4.sup.+] T cells with replication- competent proviruses is an important mechanism contributing to HIV persistence during antiretroviral therapy (ART). One approach to targeting this latent cell expansion is to inhibit mTOR, a regulatory kinase involved with cell growth, metabolism, and proliferation. Here, we determined the effects of chronic mTOR inhibition with rapamycin with or without T cell activation in SIV-infected rhesus macaques (RMs) on ART. Rapamycin perturbed the expression of multiple genes and signaling pathways important for cellular proliferation and substantially decreased the frequency of proliferating [CD4.sup.+] memory T cells (TM cells) in blood and tissues. However, levels of cell-associated SIV DNA and SIV RNA were not markedly different between rapamycin-treated RMs and controls during ART. T cell activation with an anti-CD3LALA antibody induced increases in SIV RNA in plasma of RMs on rapamycin, consistent with SIV production. However, upon ART cessation, both rapamycin and CD3LALA-treated and control-treated RMs rebounded in less than 12 days, with no difference in the time to viral rebound or post-ART viral load set points. These results indicate that, while rapamycin can decrease the proliferation of [CD4.sup.+] TM cells, chronic mTOR inhibition alone or in combination with T cell activation was not sufficient to disrupt the stability of the SIV reservoir., Introduction The advent of antiretroviral therapy (ART) has dramatically improved the life expectancy of people with HIV (PWH) infection. However, current ART regimens act by blocking de novo infection of [...]

Published
2022
Full Text
View/download PDF

3. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1

Author

de Mendoza, Carmen, Rodriguez, Carmen, Eiros, Jose Maria, Colomina, Javier, Garcia, Federico, Leiva, Pilar, Torre-Cisneros, Julian, Aguero, Jesus, Pedreira, Jose, Viciana, Isabel, Corral, Angelica, del Romero, Jorge, de Lejarazu, Raul Ortiz, and Soriano, Vincent

Subjects
HIV infection -- Development and progression, HIV infection -- Care and treatment, HIV infection -- Drug therapy, Antiviral agents -- Testing, Drug resistance, Health, Health care industry
Published
2005

4. Cytomegalovirus (CMV) and Human Immunodeficiency Virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360)

Author

Erice, A., Tierney, C., Hirsch, M., Caliendo, A.M, Weinberg, A., Kendall, M.A., and Polsky, B.

Subjects
HIV infection -- Care and treatment, HIV infection -- Genetic aspects, HIV infection -- Complications, Cytomegalovirus infections -- Care and treatment, Cytomegalovirus infections -- Genetic aspects, Cytomegalovirus infections -- Prognosis, Drug therapy, Combination -- Testing, Antiviral agents -- Testing, Health, Health care industry
Published
2003

7. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an international AIDS society--USA panel. (HIV/AIDS)

Author

Hirsch, Martin S., Brun-Vezinet, Francoise, Clotet, Bonaventura, Conway, Brian, Kuritzkes, Daniel R., D'Aquila, Richard T., Demeter, Lisa M., Hammer, Scott M., Johnson, Victoria A., Loveday, Clive, Mellors, John W., Jacobsen, Donna M., and Richman, Douglas D.

Subjects
HIV infection -- Care and treatment, Drug resistance -- Genetic aspects, Drug resistance -- Physiological aspects, Clinical trials, Antiviral agents -- Testing, Health, Health care industry
Published
2003

10. Industrial drug testing

Subjects
Antiviral agents -- Testing, Anti-HIV agents -- Testing, Mandatory drug testing -- Analysis -- Reports, Business, Health care industry
Abstract

The year was 1987. Disposable contact lenses became available for commercial distribution; the FDA approved the anti-AIDS drug AZT; and Prozac made its debut in the United States. Nineteen eighty-seven [...]

Published
2016

11. Zidovudine for early human immunodeficiency virus (HIV) infection: who, when, and how?; and The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial; Zidovudine in asymptomatic human immunodeficiency virus infection; and Early treatments for HIV: the time has come; Zidovudine for symptomless HIV infection

Author

DeNoon, Daniel J.

Subjects
HIV infection -- Physiological aspects, Zidovudine -- Evaluation, Antiviral agents -- Testing, HIV infection -- Drug therapy, Business, Health care industry
Abstract

Articles 1 & 2: 'Zidovudine for Early Human Immunodeficiency Virus (HIV) Infection: Who, When, and How?' and 'The Safety and Efficacy of Zidovudine (AZT) in the Treatment of Subjects with [...]

Published
1990

12. Peptide T and Peptide T(4-8)

Author

DeNoon, Daniel J.

Subjects
HIV (Viruses) -- Drug therapy, Peptide T -- Health aspects, AIDS (Disease) -- Drug therapy, Antiviral agents -- Testing, Biological markers -- Physiological aspects, Business, Health care industry
Abstract

PEPTIDE T and PEPTIDE T[4-8]. Chemical Name: D-ala-1-peptide-T-amide (HIV gp120 envelope glycoprotein octapeptide sequence Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr (peptide T) or pentapeptide sequence Thr-Thr-Asn-Tyr-Thr (peptide T[4-8])). Manufacturer: Rights to manufacture peptide T were [...]

Published
1990

13. Nucleoside analogs

Author

DeNoon, Daniel J.

Subjects
HIV (Viruses) -- Drug therapy, Antiviral agents -- Testing, AIDS (Disease) -- Drug therapy, Nucleoside analogs -- Health aspects, Nucleosides -- Dosage and administration, Business, Health care industry
Abstract

NUCLEOSIDE ANALOGS. See individual listings below for specific chemistry, manufacturers, and FDA status. Nucleoside analogs comprise a broad family of chemicals created by changes in the molecular configurations of nucleosides, [...]

Published
1990

14. Anti-sense oligodeoxynucleotides

Author

DeNoon, Daniel J.

Subjects
Nucleosides -- Health aspects, Immune response -- Laws, regulations and rules, Oligodeoxynucleotides -- Health aspects, Antiviral agents -- Testing, HIV (Viruses) -- Drug therapy, Business, Health care industry
Abstract

ANTI-SENSE OLIGODEOXYNUCLEOTIDES. Also Known As: hybridons; oligo(dN). Chemical Names: antisense oligodeoxynucleoside methylphosphonates (M-ODNs or OMPs) and antisense oligodeoxynucleoside phosphorothioates (S-ODNs, including ODN-1). Manufacturers: M-ODN: Vestar Inc., Pasadena, Calif. (OMP-A); S-ODN: [...]

Published
1990

15. Drug design team discovers possible new lead

Author

Cooper, Mike

Subjects
Antipsychotic drugs -- Testing, AIDS (Disease) -- Drug therapy, Haloperidol -- Health aspects, Antiviral agents -- Testing, Business, Health care industry, Haldol (Medication) -- Testing
Abstract

UCSF University of California, San Francisco (UCSF) researchers trying to develop a better strategy for finding AIDS drugs have discovered a chemical compound that blocks a critical enzyme in HIV. [...]

Published
1990

16. 99 AIDS patients said to be symptom-free after oral IFN-A treatment

Author

DeNoon, Daniel J.

Subjects
Kenya -- Health aspects, Interferon alpha -- Health aspects, Immunological adjuvants -- Testing, AIDS (Disease) -- Drug therapy, Antiviral agents -- Testing, Immune response -- Laws, regulations and rules, Business, Health care industry
Abstract

Kenya Ninety-nine of 101 AIDS patients are free of symptoms after eight weeks of treatment with an oral alpha interferon formulation, a Kenyan medical researcher told a meeting in Japan. [...]

Published
1990

17. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: a phase I-II escalating dosage trial; The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: a phase 1 study; Soluble CD4: the first step

Author

DeNoon, Daniel J.

Subjects
AIDS (Disease) -- Drug therapy, AIDS-related complex -- Drug therapy, Antiviral agents -- Testing, Biological markers -- Health aspects, Business, Health care industry, San Francisco General Hospital Medical Center -- Research, Massachusetts General Hospital (Boston, Massachusetts) -- Research
Abstract

'Recombinant Soluble CD4 Therapy in Patients with the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex: A Phase I-II Escalating Dosage Trial', and 'The Safety and Pharmacokinetics of Recombinant Soluble CD4 [...]

Published
1990

18. ddC

Author

DeNoon, Daniel J.

Subjects
United States. National Institute of Allergy and Infectious Diseases -- Research, AIDS-related complex -- Drug therapy, HIV (Viruses) -- Drug therapy, Zalcitabine -- Evaluation, Nucleoside analogs -- Testing, AIDS (Disease) -- Drug therapy, Antiviral agents -- Testing, Business, Health care industry
Abstract

ddC. Also Known As: DDC, ddCyd, DOC, D2C. Chemical Name: 2',3'-dideoxycytidine. Manufacturer: Hoffmann-LaRoche Inc., Nutley, N.J., under a licensing agreement with the U.S. National Institutes of Health. FDA Status: IND. [...]

Published
1990

19. GLQ223

Author

DeNoon, Daniel J.

Subjects
Antiviral agents -- Testing, HIV (Viruses) -- Drug therapy, Macrophages -- Physiological aspects, Materia medica, Vegetable -- Research, Business, Health care industry, GLQ223 (medication) -- Health aspects
Abstract

GLQ223. Also Known As: compound Q (although compound Q is actually the name of a less pure plant extract containing the protein called GLQ223); trichokirin. Chemical Name: trichosanthin. Developer: Genelabs [...]

Published
1990

20. Dextran sulfate

Author

DeNoon, Daniel J.

Subjects
Sodium sulfate -- Health aspects, Antiviral agents -- Testing, Anticoagulants (Medicine) -- Testing, HIV (Viruses) -- Drug therapy, Immune response -- Laws, regulations and rules, Business, Health care industry
Abstract

DEXTRAN SULFATE. Also Known As: UA001. Manufacturer: Ueno Fine Chemicals Industry Ltd., Osaka, Japan. FDA Status: IND for AIDS. Since being developed in the 1950s, the sulfated polysaccharide dextran sulfate [...]

Published
1990

21. BuDNJ

Author

DeNoon, Daniel J.

Subjects
Antiviral agents -- Testing, Pathology, Cellular -- Drug therapy, HIV (Viruses) -- Drug therapy, Business, Health care industry
Abstract

BuDNJ. Also Known As: SC48334. Chemical Name: N-butyldeoxynojirimycin. Manufacturer: G.D. Searle & Co., Skokie, Ill. FDA Status: IND. Cambridge researcher Abraham Karpas and colleagues have suggested that aminosugar-type compounds could [...]

Published
1990

22. Panacos Pharmaceuticals has begun a Phase I clinical trial

Subjects
Panacos Pharmaceuticals Inc. -- Research, Pharmaceutical industry -- Research, Antiviral agents -- Testing, Anti-HIV agents -- Testing, Clinical trials, Health care industry, Pharmaceuticals and cosmetics industries
Abstract

* Panacos Pharmaceuticals has begun a Phase I clinical trial of its small molecule HIV drug candidate [...]

Published
2004

23. Alpha interferon

Author

DeNoon, Daniel J.

Subjects
Kaposi's sarcoma -- Drug therapy, Interferon -- Testing, Biological response modifiers -- Testing, Interferon alpha -- Testing, AIDS (Disease) -- Drug therapy, Antineoplastic agents -- Testing, Antiviral agents -- Testing, Business, Health care industry
Abstract

ALPHA INTERFERON At first thought to be a single substance, natural alpha interferon contains many of the IFN-[alpha] subtypes that have been identified. Natural alpha interferon is induced from leukocyte [...]

Published
1989

24. Dextran sulfate

Author

DeNoon, Daniel J.

Subjects
Sodium sulfate -- Testing, AIDS-related complex -- Drug therapy, Antiviral agents -- Testing, AIDS (Disease) -- Drug therapy, Business, Health care industry
Abstract

DEXTRAN SULFATE. Since being developed in the 1950s, the sulfated polysaccharide dextran sulfate has been widely used in Japan as an anticoagulant and has demonstrated low toxicity. In vitro experiments [...]

Published
1989

25. AZT

Author

DeNoon, Daniel J.

Subjects
AIDS-related complex -- Drug therapy, AIDS (Disease) -- Drug therapy, Antiviral agents -- Testing, Zidovudine -- Testing, Business, Health care industry
Abstract

AZT. Also Known As: azidothymidine, zidovudine, BW A509U, Compound S. Trade Name: Retrovir (AZT is also a registered trademark of Burroughs Wellcome). Chemical Name: 3'-azido-3'-deoxythymidine. Manufacturer: Burroughs Wellcome Co., Research [...]

Published
1989

26. Clinical trials of FLV23/A stopped

Subjects
AIDS (Disease) in children -- Romania, AIDS (Disease) -- Drug therapy, Antiviral agents -- Testing, Business, Health care industry
Abstract

Romania At the request of the Ministry of Health of Romania, a Commission of the World Health Organization (WHO) was invited to evaluate the trial of a drug known as [...]

Published
1990

27. Detailed drug evaluation of anti-AIDS agents

Subjects
United States. National Cancer Institute -- Contracts, AIDS (Disease) -- Drug therapy, Antiviral agents -- Testing, Business, Health care industry
Abstract

AUTHORS: Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute. Contact: Mr. Johnny Jordan, Contract Specialist Treatment Contracts Section, Research Contracts Branch, National Cancer Institute, Executive Plaza South, Room [...]

Published
1990

28. University of Miami researcher Fischl criticized

Subjects
United States. National Institutes of Health -- Research, AIDS (Disease) -- Drug therapy, Antiviral agents -- Testing, Business, Health care industry, AIDS Coalition to Unleash Power -- Demonstrations and protests
Abstract

Members of ACT-UP criticized Dr. Margaret Fischl at the VI International Conference on AIDS, claiming that her research has led to the death of AIDS patients. The group distributed leaflets [...]

Published
1990

29. New studies urge use of unique animal model for AIDS research

Subjects
SyStemix Inc. -- Research, Pharmaceutical industry -- Research, AIDS (Disease) -- Models, Antiviral agents -- Testing, HIV infection -- Physiological aspects, Mice as laboratory animals -- Usage, Business, Health care industry
Abstract

SyStemix Inc. In seven presentations by SyStemix Inc., Palo Alto, California, at the VI International Conference on AIDS, researchers called for more widespread use of the unique SCID-hu mouse model [...]

Published
1990

30. A need for a multi-parameter virological testing in screening potential AIDS drugs in vitro

Author

DeNoon, Daniel J. and Cooper, Mike

Subjects
AIDS (Disease) -- Drug therapy, Antiviral agents -- Testing, HIV (Viruses) -- Reproduction, Business, Health care industry
Abstract

AUTHORS: D.J. Volsky, N. Hamblet, B. Volsky, M.G. Pellegrino and G. Li. Molecular Virology Laboratory, St. Luke's/Roosevelt Hospital Center and Columbia University College of Physicians and Surgeons, New York. According [...]

Published
1990

31. DDC expanded access trial to begin June 25

Author

DeNoon, Daniel J.

Subjects
Hoffmann-La Roche Inc. -- Research, Pharmaceutical industry -- Research, Nucleoside analogs -- Health aspects, Zalcitabine -- Health aspects, AIDS (Disease) -- Drug therapy, Antiviral agents -- Testing, AIDS-related complex -- Drug therapy, Business, Health care industry
Abstract

Hoffmann-La Roche Inc. Hoffman-La Roche Inc. has announced FDA approval of an expanded access program for the experimental anti-HIV drug 2',3'-dideoxycytidine (ddC) in which physicians will be able to obtain [...]

Published
1990

32. Interferon inducers and other biological response modifiers in murine retrovirus models

Author

DeNoon, Daniel J. and Cooper, Mike

Subjects
Biological response modifiers -- Health aspects, AIDS (Disease) -- Drug therapy, Antiviral agents -- Testing, AIDS (Disease) -- Models, Retroviruses -- Physiological aspects, Business, Health care industry
Abstract

AUTHORS: M.A. Ussery, P.L. Black, J.T. Rankin Jr. and M.A. Chirigos. U.S. Food and Drug Administration, Rockville, Md.; Southern Research Institute-Frederick Research Center, Frederick, Md.; and USAMRIID, Ft. Detrick, Md. [...]

Published
1990

33. Marked inhibition of human immunodeficiency virus type 1 and type 2 by alpha-(1-3)- and alpha-(1-6)-mannose-specific plant lectins

Author

DeNoon, Daniel J. and Cooper, Mike

Subjects
Antiviral agents -- Testing, HIV infection -- Drug therapy, Materia medica, Vegetable -- Testing, Plant lectins -- Health aspects, Business, Health care industry
Abstract

AUTHORS: J. Balzarini, D. Schols, E. Van Damme, W. Peumans and E. De Clercq. Rega Institute for Medical Research and Laboratory for Cytopathology and Plant Protection, Faculty of Agronomy, Leuven [...]

Published
1990

34. Inhibition of human immunodeficiency virus type 1 replication and cytopathicity by synthetic soluble catecholamine melanins in vitro

Author

DeNoon, Daniel J.

Subjects
Organic pigments -- Health aspects, Antiviral agents -- Testing, Melanin -- Health aspects, HIV infection -- Drug therapy, Business, Health care industry
Abstract

SOURCE: Biochemical and Biophysical Research Communications, April 16, 1990; 168(1):200-205. Three synthetic soluble melanins are able to inhibit HIV infection and syncytium formation in vitro, Vanderbilt University researchers report. Melanins, [...]

Published
1990

35. DDI shows promise in phase I tests

Author

Cooper, Mike

Subjects
HIV infection -- Drug therapy, Antiviral agents -- Testing, Didanosine -- Evaluation, AIDS (Disease) -- Drug therapy, Business, Health care industry
Abstract

U.S. NCI Two studies indicate that dideoxyinosine (DDI) can work against HIV without excessive side effects. In March, the drug's manufacturer, Bristol-Myers Squibb Co., reported that DDI seemed to cause [...]

Published
1990

36. Rational design of peptide-based HIV proteinase inhibitors

Author

DeNoon, Daniel J.

Subjects
HIV infection -- Drug therapy, Antiviral agents -- Testing, Proteases, HIV (Viruses) -- Reproduction, Business, Health care industry
Abstract

SOURCE: Science, April 20, 1990; 248(4953):358-361. After synthesizing more than 100 compounds mimicking the HIV protease enzyme, a group of Roche Ltd. researchers have developed a highly potent HIV inhibitor [...]

Published
1990

37. Inhibition of HIV progression by dithiocarb

Author

DeNoon, Daniel J.

Subjects
Antiviral agents -- Testing, HIV infection -- Drug therapy, Business, Health care industry
Abstract

SOURCE: The Lancet, March 24, 1990; 335(8691):679-682. A significant delay in disease progression and decreased frequency of HIV-associated diseases and symptoms were observed during 18 months' follow-up of patients treated [...]

Published
1990

38. Modification of human immunodeficiency viral replication by pine-cone extracts

Author

DeNoon, Daniel J.

Subjects
Materia medica, Vegetable -- Testing, Pine -- Health aspects, Antiviral agents -- Testing, HIV infection -- Drug therapy, Pine cones -- Health aspects, HIV (Viruses) -- Reproduction, Business, Health care industry
Abstract

SOURCE: AIDS Research and Human Retroviruses, February 1990; 6(2):205-217. Two non-toxic extracts from cones of the Japanese white pine tree inhibit HIV replication in both T-cell and monocyte/macrophage cultures, researchers [...]

Published
1990

39. Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro

Author

DeNoon, Daniel J.

Subjects
HIV infection -- Drug therapy, T cells, Antiviral agents -- Testing, Nucleoside analogs -- Health aspects, Business, Health care industry
Abstract

SOURCE: Antimicrobial Agents and Chemotherapy, February 1990, 34(2):287-294. Two novel carbocyclic analogs of oxetanocin inhibit HIV replication in both T-cell and monocyte/macrophage cultures, reports a research team from the NCI, [...]

Published
1990

40. Effect of tamoxifen on regulation of viral replication and human immunodeficiency virus (HIV) long terminal repeat-directed transcription in cells chronically infected with HIV-1

Author

DeNoon, Daniel J.

Subjects
Antineoplastic agents -- Testing, Tamoxifen -- Physiological aspects, Antiviral agents -- Testing, Estrogen -- Antagonists, Genetic transcription -- Physiological aspects, HIV (Viruses) -- Genetic aspects, HIV infection -- Drug therapy, Business, Health care industry, New York Hospital/Cornell Medical Center -- Research, Cornell University. Weill Medical College -- Research
Abstract

SOURCE: Blood, February 1, 1990; 75(3):696-703. The non-steroidal estrogen antagonist tamoxifen blocks in-vitro trans-activation of HIV in both monocytes and T cells at clinically achievable concentrations, report Cornell University Medical [...]

Published
1990

41. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation

Author

DeNoon, Daniel J.

Subjects
Upjohn Co. -- Research, HIV infection -- Drug therapy, Biotechnology industry -- Research, Protease inhibitors -- Health aspects, Antiviral agents -- Testing, Business, Health care industry
Abstract

SOURCE: Science, January 26, 1990; 247(4941):454-456. Researchers at Upjohn Co. have developed U-81749, an inhibitor of HIV-1 protease that acts at concentrations 100 times less than that which inhibits human [...]

Published
1990

42. Companies may jointly develop new drugs

Author

Cooper, Mike

Subjects
Genentech Inc. -- Research, Roche Holding Ltd. -- Research, Antiviral agents -- Testing, AIDS (Disease) -- Drug therapy, Biotechnology industry -- Research, Biological markers -- Testing, Business, Health care industry
Abstract

Genentech/Roche Genentech Inc., South San Francisco, California, and Roche Holdings Ltd., Basel, Switzerland, are reviewing current drug research to consider whether to jointly conduct research in light of Roche's recent [...]

Published
1990

43. AIDS effort to be redirected away from development of soluble T4

Author

Cooper, Mike

Subjects
SmithKline Beecham Corp. -- Research, Invitron Corp. -- Research, AIDS (Disease) -- Drug therapy, Antiviral agents -- Testing, Bacteriophage T4 -- Health aspects, Pharmaceutical industry -- Research, Business, Health care industry
Abstract

SmithKline Invitron Corporation, St. Louis, has announced that it has been advised by SmithKline Beecham that SmithKline was redirecting the focus of its AIDS development program away from soluble T4 [...]

Published
1990

45. Synthetic compound appears to reduce HIV replication

Author

Cooper, Mike

Subjects
Upjohn Co. -- Research, HIV infection -- Drug therapy, Pharmaceutical industry -- Research, Antiviral agents -- Testing, Business, Health care industry
Abstract

Upjohn Company Researchers from the Upjohn Company report, in Science, that a synthetic compound, U-81749, has been shown to reduce the level of infectious HIV particles in infected immune cells [...]

Published
1990

46. New drug called 'most specific and potent' anti-HIV agent ever

Author

DeNoon, Daniel J.

Subjects
HIV infection -- Drug therapy, Antiviral agents -- Testing, Business, Health care industry
Abstract

Belgium Six healthy human volunteers have had no significant toxic effects after taking a single dose of a highly selective new drug with powerful anti-HIV-1 activity. Reporting in the current [...]

Published
1990

47. Medical school drops charges for patients in drug studies

Author

Cooper, Mike

Subjects
AIDS (Disease) -- Research, AIDS virus carriers -- Health aspects, Antiviral agents -- Testing, Business, Health care industry, University of California, Los Angeles. David Geffen School of Medicine -- Services
Abstract

UCLA After public criticism over its policy of charging fees to screen patients for experimental AIDS drug studies, the University of California, Los Angeles, Medical School says it will no [...]

Published
1990

48. 9-(2-phosphonylmethoxethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-moloney murine sarcoma virus activity in vivo

Author

DeNoon, Daniel J.

Subjects
HIV (Viruses) -- Drug therapy, Sarcoma -- Drug therapy, Phosphonates -- Testing, Antiviral agents -- Testing, Business, Health care industry
Abstract

SOURCE: European Journal of Clinical Microbiology & Infectious Diseases, December 1989; 8(12):1043-1047. The acyclic nucleotide phosphonate derivative 9-(2-phosphonylmethoxethyl)-2,6-diaminopurine (PMEDAP) is the most potent in vivo antiretroviral agent ever reported, a [...]

Published
1990

49. Papaverine

Author

DeNoon, Daniel J.

Subjects
Alkaloids -- Testing, Antiviral agents -- Testing, HIV infection -- Drug therapy, Papaverine -- Testing, Muscle relaxants -- Testing, Business, Health care industry
Abstract

PAPAVERINE. Chemical Formula: C20H21NO4. Manufacturer: papaverine hydrochloride is generically produced by several manufacturers. Status: approved as an ethical pharmaceutical for relief of cerebral and peripheral ischemia. A benzyl isoquinoline alkaloid [...]

Published
1990

50. Suramin

Author

DeNoon, Daniel J.

Subjects
Suramin sodium -- Evaluation, Antiviral agents -- Testing, HIV (Viruses) -- Drug therapy, Antiparasitic agents -- Testing, Business, Health care industry
Abstract

SURAMIN. Also Known As: germanin, sodium suramin, suraminum natricum, Bayer 205, Fourneau 309, Naganium, Naganol. Manufacturer: Bayer Pharmaceuticals, West Haven, Conn. FDA Status: IND for AIDS. Suramin is the symmetrical [...]

Published
1990

Catalog

Books, media, physical & digital resources
See catalog results